topiramate and Cough

topiramate has been researched along with Cough* in 2 studies

Other Studies

2 other study(ies) available for topiramate and Cough

Article	Year
As a rare cause of drug-induced cough: topiramate. Acta neurologica Belgica, 2012, Volume: 112, Issue:2 The most common causes of chronic cough in nonsmokers are postnasal drip syndrome, asthma, and gastroesophageal reflux disease. Drugs are also important in the etiology of resistant cough. Most common drugs inducing cough are the ACE inhibitors. Many drugs other than ACE inhibitors can also cause dry cough and one among them is topiramate. It is a new generation, efficacy-proved antiepileptic drug that is used widely for migraine prophylaxis in many countries. Most common adverse events of topiramate are paresthesia, cognitive symptoms, fatigue, insomnia, nausea, loss of apetite, anxiety, and dizziness. There is only one case report about topiramate associated cough in the literature. The present report refers to a patient, presenting with cough who is on topiramate treatment for migraine prophylaxis. Topics: Adult; Cough; Female; Fructose; Humans; Migraine Disorders; Neuroprotective Agents; Topiramate	2012
Topiramate-induced intractable cough during migraine prophylaxis. Headache, 2010, Volume: 50, Issue:2 Topiramate is a highly effective drug in migraine prophylaxis and is considered a first-line treatment. The evidence for the efficacy of topiramate is based upon the results of several large, randomized, double-blind, placebo-controlled trials. Adverse events (AEs) are common and require discontinuation of the treatment in about 20-25% of patients, but they are rarely severe. There are reviews regarding topiramate-related AEs representing a large number of patients treated in controlled trials. The most common AEs are weight loss, dizziness, somnolence, abnormal thinking, fatigue, ataxia, confusion, paresthesias, impaired concentration, nervousness, amnesia, and language difficulties. The development of cough has never been reported as an AE during topiramate prophylaxis for migraine. We present 3 cases in which the prophylactic treatment for migraine with topiramate was discontinued due to the onset of primary intractable coughing. Topics: Adult; Anticonvulsants; Brain; Cough; Dose-Response Relationship, Drug; Female; Fructose; Humans; Iatrogenic Disease; Male; Middle Aged; Migraine Disorders; Topiramate	2010

Article

Year

As a rare cause of drug-induced cough: topiramate.

Acta neurologica Belgica, 2012, Volume: 112, Issue:2

The most common causes of chronic cough in nonsmokers are postnasal drip syndrome, asthma, and gastroesophageal reflux disease. Drugs are also important in the etiology of resistant cough. Most common drugs inducing cough are the ACE inhibitors. Many drugs other than ACE inhibitors can also cause dry cough and one among them is topiramate. It is a new generation, efficacy-proved antiepileptic drug that is used widely for migraine prophylaxis in many countries. Most common adverse events of topiramate are paresthesia, cognitive symptoms, fatigue, insomnia, nausea, loss of apetite, anxiety, and dizziness. There is only one case report about topiramate associated cough in the literature. The present report refers to a patient, presenting with cough who is on topiramate treatment for migraine prophylaxis.

Topics: Adult; Cough; Female; Fructose; Humans; Migraine Disorders; Neuroprotective Agents; Topiramate

2012

Topiramate-induced intractable cough during migraine prophylaxis.

Headache, 2010, Volume: 50, Issue:2

Topiramate is a highly effective drug in migraine prophylaxis and is considered a first-line treatment. The evidence for the efficacy of topiramate is based upon the results of several large, randomized, double-blind, placebo-controlled trials. Adverse events (AEs) are common and require discontinuation of the treatment in about 20-25% of patients, but they are rarely severe. There are reviews regarding topiramate-related AEs representing a large number of patients treated in controlled trials. The most common AEs are weight loss, dizziness, somnolence, abnormal thinking, fatigue, ataxia, confusion, paresthesias, impaired concentration, nervousness, amnesia, and language difficulties. The development of cough has never been reported as an AE during topiramate prophylaxis for migraine. We present 3 cases in which the prophylactic treatment for migraine with topiramate was discontinued due to the onset of primary intractable coughing.

Topics: Adult; Anticonvulsants; Brain; Cough; Dose-Response Relationship, Drug; Female; Fructose; Humans; Iatrogenic Disease; Male; Middle Aged; Migraine Disorders; Topiramate

2010